Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Novabay Reported Preliminary Q4 2023 Sales Of $3.7M, Consisting Of $0.9M From Its DERMAdoctor Skincare Segment And $2.8M From Its Eyecare And Wound Care Segment Versus Consensus Of $3.4M

Author: Benzinga Newsdesk | March 14, 2024 08:06am

Operating loss for the fourth quarter of 2023 is expected to be approximately $3.2 million, due primarily to the $2.7 million loss in the DERMAdoctor skincare segment. The dermadoctor skincare segment loss includes a $2.5 million non-cash impairment of goodwill and indefinite lived and long-lived assets related to the business segment

Posted In: NBY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist